Angelini Pharma SpA and JCR Pharmaceuticals Co. Ltd. have entered into an exclusive global development and commercialization agreement for the development of novel biologic therapies that applies J-Brain Cargo blood-brain barrier penetrating technology for the treatment of epilepsy, applying undisclosed effectors.